New Randox Online Store launched with exclusive offers and discounts
New Randox Online Store launched with exclusive offers and discounts
10 September 2019
New Randox Online Store
Randox launches new Online Store with exclusive offers and discounts
Global diagnostics company Randox Laboratories has unveiled a new Online Store aimed at facilitating more convenient and efficient product purchase for its customers.
Selling the firm’s world-renowned Quality Control, Reagents, dedicated RX series kits and consumables online, the website offers customers the opportunity to avail of the most exclusive offers and discounted prices, as well as ‘Last Chance To Buy’ kits not to be found anywhere else.
The development of the store began in late 2018 and was concluded earlier this year.
Lynsey Adams, Randox Quality Control Marketing Manager commented;
“At Randox our clients are always our top priority and as such we are extremely pleased to be able to launch our new online store, facilitating even more convenient and easy-to-use product purchase for our customers.
“Consumer buying habits are ever-changing and it is important that we keep apace to meet customers’ needs and expectations. Being able to order our quality diagnostic products via the simple click of a button will revolutionise the way hospitals, laboratories and veterinary clinics can access the Randox products they require to complete their testing.”
The new Randox Online Store is made up of five sub-sections – Product Catalogue, New Products, Best Sellers, Clearance, and Last Chance To Buy. Customers can therefore now browse directly a range of additional and supplementary diagnostic products including those which have been discounted due to short expiry or discontinuation, and each month, a selection of featured products on special offer in the clearance section.
Lynsey continued;
“The Randox Online Store is a complimentary resource for our Business Development team, who can now offer, in addition to the competitively priced quality control, reagents and Rx series analysers in our testing menu, a discounted selection of surplus stock and discontinued kits that may previously have gone unused.
“Not only is our Online Store improving the customer experience, it is having a significantly positive impact on the environment by reducing waste.”
There is currently a live 20% discount valid on a customer’s first purchase on the Randox Online Store when they sign up to the store’s mailing list.
A simple and efficient checkout process shows the total cost of the order, including shipping costs and VAT, and payments are powered by ‘WorldPay’ which facilitates a wide variety of payment options including PayPal.
To visit the Randox Online Store and view our range of diagnostic products for sale, please visit https://store.randox.com/
For further information please email market@randox.com or contact your Randox Representative.
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
DIKI: Drug Induced Kidney Injury Array from Randox Biosciences
Randox Biosciences introduces the innovative Randox Drug Induced Kidney Injury Array (DIKI). The new panels allow superior monitoring of nephrotoxicity for enhanced safety in drug development. It has been developed to identify four early stage markers of DIKI by screening for the biomarkers KIM-I, NGAL, Cystatin C, and Clusterin which have been identified as more sensitive than transitional testing methods to enhance accurate diagnosis of DIKI.
Our Biochip Array Technology enables multiplex immunoassay testing. The DIKI panel of 4 markers is combined on a single biochip, enabling simultaneous results from each patient sample, delivering:
- Excellent inter-assay precision and required sensitivity
- Superior specificity
- Lower sample volume
- Fast turnaround time
- Safer drug development
With the number of hospitalised patients who develop a drug-induced renal problem due to the numbers of potent drugs have been added to the therapeutic arsenal in recent year1 – the DIKI can have a detrimental effect on a person’s health and wellbeing. Blakely stated that “drug-induced nephrotoxic contributes to 8 to 60% of all cases of AKI seen on the intensive care unit (ICU)”.2 Randox offers a 4-plex Drug Induced Kidney Injury test which detects early stage toxicity across the nephron, assisted through composite measurement. Earlier and more reliable detection of drug-induced kidney injury would improve clinical care and help to streamline drug-development. (Dieterle et al., 2010)3.
The poor sensitivity of serum creatinine for detecting and monitoring DIKI is well documented in academic journals. As a result, for early phase trials European Medicines Agency (EMA) and Food and Drug Administration (FDA) are encouraging the use of more novel urinary biomarkers alongside conventional safety monitoring. The new panel will be able to identify the levels of toxicity present in the kidneys which is classified as one of the most common side effects of drug development trials.
The new Randox Drug Induced Kidney Injury (DIKI) panel can help you conduct clinical trials safer and faster. For more information contact info@randoxbiosciences.com.
Flexible Drug and Alcohol Testing Methods
06 August 2019
Flexible Drug and Alcohol Testing Methods
At Randox Testing Services our complete testing solutions include flexible drug and alcohol testing methods that can be tailored to meet our customer needs. In all aspects of testing we ensure the accuracy and reliability of results and utilise strict chain of custody procedures across all our testing methods.
To guarantee the most effective form of testing our dedicated Account Managers make informed recommendations to our customers on what type of testing best suits their business needs. The different methods are outlined below along with the sample types that can be tested:
Drug and Alcohol Testing Methods
-
Abstinence Monitoring
Conducted as a follow up on a confirmed positive drug or alcohol test. If an employer provides support to an employee who has had a confirmed positive drug or alcohol test, this type of testing may be used to help with rehabilitation.
-
Post-Incident
Used to determine if drugs or alcohol may have contributed to an accident/incident in the workplace. This type of testing can be an effective tool in accident investigations and it is our recommendation that should an incident occur, all employees involved should be tested.
-
Pre-Employment
This is the most popular type of workplace testing especially in industries which have safety critical roles. This type of testing is an essential part of a company’s recruitment process and clearly states the company’s position on drug and alcohol misuse for any potential employee.
-
Random
A popular type of testing within workplaces as it acts as a deterrent to drug and alcohol abuse. A company’s drug and alcohol testing policy should clearly outline that they carry out random workplace testing ensuring employees do not know when the event is planned.
-
With-Cause
Performed when a company is suspicious that an employee may be currently under the influence of alcohol or misusing drugs. This suspicion is normally raised if an employee is acting out of character and there has been observed different behaviours.
Sample Types
-
Urine (Alcohol and Drugs)
The most common sample type for drug testing and offers a longer detection window than oral fluid for drugs.
-
Oral Fluid (Drugs only)
Oral fluid testing analyses a saliva sample for parent drugs and their metabolites, providing analysis of short-term drug abuse.
-
Hair (Alcohol and Drugs)
A hair drugs test offers a longer window of detection than alternative testing and can provide a detailed view or overall picture of drug use. Detection window is based on hair length with 1cm of head equating to approximately 1 month of detection.
-
Breath (Alcohol only)
Breath can be tested for alcohol using hand-held devices which provide immediate results. These devices can gauge blood alcohol content (BAC) by measuring deep lung air.
About Randox Testing Services
Randox Testing Services is a market leader in the drug and alcohol testing industry. Our expertise is relied upon by a range of leading safety-critical companies across the world.
We pride ourselves on helping our customers improve the health and safety of their working environment through helping them implement a comprehensive substance misuse policy. Our expertise within this industry allows us to craft customised packages to meet the testing needs of any workplace. Our drug and alcohol testing methods are flexible to adapt to any changes and our testing processes are accurate, to guarantee reliable results.
Contact us today be at testingservices@randox.com or call 028 9445 1011 to speak to one of our experts.
Want to know more?
Contact us or visit our website to read more.
Randox QC unveils brand new multi-analyte commutable Acusera Infectious Disease Controls
Randox Quality Control is set to introduce its brand new Acusera Infectious Disease (Serology) Controls at the American Association for Clinical Chemistry 2019, designed to deliver a cost-effective, high quality solution for the analysis of infectious diseases whilst producing trustworthy results.
The Infectious Disease Serology Internal Quality Controls will include quality control material for Lyme Disease, ToRCH, Epstein-Barr virus, HIV, Hepatitis A virus, Human T-lymphotropic virus, Cytomegalovirus, and Varicella zoster virus (Chickenpox or Shingles).
Manufactured from human plasma, each control is designed to react to the test system in the same manner as the patient sample, helping to meet ISO 15189:2012 requirements while also reducing inconvenient shifts in QC results when reagent batches are changed.
Lynsey Adams, Randox Quality Control Manager, commented;
“These controls are the first of their kind on the market to be used on a wide range of immunoassay analysers. Unlike the current practice of analyser-specific tests, these controls can be used across a wide range of laboratory technologies and, with a working stability of 60 days at 2°c to 8°c, waste and costs are kept to a minimum.”
Acusera Infectious Disease (Serology) Controls are also multi-analyte and therefore, testing can be consolidated to just a small number of vials, saving laboratories valuable space and time. A single control can be used to assess performance across a range of analytes.
Key benefits of the Acusera Infectious Disease Controls;
- All samples are provided in a user-friendly, liquid, ready-to-use format
- Manufactured from human plasma, each control reacts to the test system in the same manner as a patient sample
- Designed to deliver an independent, unbiased assessment of performance with any immunoassay instrument
- Working stability of 60 days ensures waste and costs are kept to a minimum
- Multi-marker controls help reduce the number of individual controls required
- Designed to challenge clinically-relevant levels, samples will ensure accurate and reliable instrument performance
Ideal for microbiology and virology laboratories, blood banks, public health laboratories or clinical laboratories performing serology testing, Randox QC’s Acusera Infectious Disease (Serology) Controls are set to revolutionise serology testing and provide reliable, accurate results time and time again.
For further information please email acusera@randox.com, visit www.randoxqc.com or tel: +44 (0) 28 9442 2413 / fax: +44 (0) 28 9445 2912
Multiplex biochip for accurate differentiation of stroke types launched at AACC
A ground-breaking new test which improves the accuracy of stroke diagnosis has been developed by Randox scientists.
The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.
With a unique ability to differentiate between ischaemic and haemorrhagic stroke, the Randox Stroke Biochip takes less than 30 minutes to complete – making sure patients get the right diagnosis as fast as possible.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, whose team developed the test, commented;
“There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time, yet too often the window closes before a diagnosis is made. For doctors, nothing is more frustrating.
“Excellent work has been undertaken to assist the public in recognising the signs of a stroke so people can get to hospital as quickly as possible. Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”
Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.
Benefits of the Randox Stroke Biochip
- Results in 30 minutes on the Evidence MultiSTAT
- Unique solution for stroke classification
- Differentiation of ischaemic and haemorrhagic stroke
- Guarantees rapid thrombolytic therapy ensuring better patient outcomes
John Lamont, R&D Director for Randox Laboratories, explained the benefits of the Stroke Biochip;
“While patients undergo a CT scan to confirm either the presence or lack of a haemorrhagic stroke, a blood test on the Randox Biochip can be run on our innovative point-of-care analyser, the Evidence MultiSTAT, to identify the same for an ischaemic stroke.
“For the almost 90% of stroke patients who are ruled out for haemorrhagic stroke1, the Randox Biochip will then accelerate decision making for clinicians with regards to thrombolytic therapy.
“Any treatment is most effective if started as soon as possible after the stroke occurs, and so every minute that passes without a diagnosis is likely to leave a permanent mark on a stroke patient’s future health and lifestyle. The vitally important diagnostic information from the Randox Stroke Biochip facilitates accurate stroke classification, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy, ensuring a better patient outcome for ischaemic stroke sufferers, for whom time is of the essence.”
Whilst the Randox Stroke Biochip is currently being used as complementary testing in parallel with CT scanning, Mr Lamont is confident of a more prominent role for the test in the future patient pathway;
“The Biochip has the potential to really revolutionise the stroke diagnosis pathway as we currently know it. The accessibility of this type of blood testing could potentially extend its use beyond the A&E department, to ambulances and even the home, in the form of a hand-held testing device.”
For further information about our pioneering Stroke Biochip please visit us at stand 1101 at this year’s AACC or follow the links below.
Want to know more?
Contact us or visit our Stroke Biochip page to learn more.
Related Products
MULTISTAT
EVIDENCE SERIES
BIOCHIP
CEREBRAL ARRAY
H-FABP for Acute Kidney Injury Testing Revealed by Randox
A new testing application for the biomarker Heart-Type Fatty Acid-Binding Protein (H-FABP) has been announced by global diagnostics company Randox Laboratories.
Whilst H-FABP is most commonly recognized as an early biomarker of myocardial infarction, the assay’s clinical utility in cardiac surgery associated acute kidney injury (CSA-AKI) is notable. Studies have shown that patients who developed AKI following cardiac surgery had elevated levels of H-FABP both pre-and postoperatively compared to the patients who did not.
Susan Hammond, Randox Product Specialist, explained the new application for H-FABP;
“Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognized postoperative complication of cardiac surgery and is the second most common cause of AKI in the intensive care unit (ICU) – occurring in up to 30% of patients.
“Several AKI studies exist focusing on the measurement of H-FABP levels before, during and after cardiac surgery, one of which found that the post-operative H-FABP levels in patients who experienced any AKI increased 8-fold. It was also noted that the levels of those with severe AKI increased 13-fold and that 10.8% of patients who died from subsequent AKI all had elevated pre-operative levels of H-FABP.
“The Randox H-FABP assay is therefore an independent marker of AKI following cardiac surgery, and can furthermore be used as a CSA-AKI risk assessment assay even in advance of the procedure.”
It has been identified that certain patient groups are more susceptible to CSA-AKI and vulnerability can depend on age, sex, pre-existing cardiac dysfunction, pre-existing chronic kidney disease (CKD), previous cardiac surgery or comorbidity.
Susan Hammond added;
“The ability to include biomarkers that aid in the risk assessment and treatment plan management of a patient is significant. Utilizing H-FABP alongside traditional biomarkers to assess CSI-AKI risk allows the clinician to gain stronger clinical insight in how to improve patient outcomes.”
Key Benefits of the Randox H-FABP assay
A niche product from Randox meaning that Randox are one of the only manufacturers to offer the H-FABP assay in an automated biochemistry format
CE marked for diagnostic use
Automated assay offering a more convenient and time efficient method for H-FABP measurements compared to traditional testing
Exceptional correlation of r=0.97 when compared against other commercially available methods
Applications available detailing instrument-specific settings for the convenient use of the Randox H-FABP assay on a wide range of clinical chemistry analysers
Liquid ready-to-use format for convenience and ease-of-use
Latex enhanced immunoturbidimetric method delivering high performance compared to traditional ELISA testing
Rapid results within fourteen minutes, depending on the analyser.
Wide measuring range of 0.747 – 120ng/ml for the early detection of clinically important results
Dedicated H-FABP controls and calibrator available offering a complete testing package
Randox launches whole pathogen Blood Borne Virus Controls at AACC
Whole pathogen Blood Borne Virus (BBV) controls have been brought to market by global diagnostics company Randox Laboratories.
The molecular controls, available under the brand name Qnostics, are versatile in monitoring the presence of BBVs, including HIV, Hepatitis B and Hepatitis C.
For use with molecular methods, the controls are manufactured using whole pathogens and therefore mimic the patient sample, providing the best sample matrix for laboratories.
Lynsey Adams, Randox Quality Control Manager, explained;
“We’re delighted to be able to bring to market these whole pathogen Blood Borne Virus Controls, which are designed to help molecular laboratories effectively manage assay performance.
“Using whole pathogens in the development of the controls ensures we meet the demands of today’s molecular diagnostics laboratories by monitoring the entire testing process.”
The Molecular BBV controls from Randox, which are liquid frozen for user convenience and ease of use, will aid microbiology and virology laboratories to monitor assay drift and ultimately will help to ensure accurate test system performance. Each control is designed to be medium positive and are suitable for use with a variety of molecular workflows.
Lynsey added;
“These versatile Blood Borne Virus controls can be used in the daily monitoring of assay performance, but are equally applicable for use in the validation/verification of new assays, and may also be used for troubleshooting after poor EQA performance.”
Randox Blood Borne Virus Molecular Controls are manufactured to ISO 13485 standards and calibrated against an independent Internal Reference Material. Also included within the Qnostics BBV range are Molecular Q panels. Each molecular Q panel includes a negative, low, medium and high positive sample designed to cover more of the assays measuring range.
Key Features and Benefits of Randox Blood Borne Virus Qnostics Controls:
- Third party controls as recommended by ISO 15189:2012
- Specifically designed to meet the demands of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT)
- Suitable for use across a wide range of molecular assays to monitor the entire molecular workflow from extraction to amplification and detection
- Flexible and suitable for use with the majority of commercial and in-house molecular methods
- Traceable to the current relevant WHO International Standards and characterised by digital PCR
- Liquid frozen for user convenience and ease of use, with no additional preparation required
- Calibrated against an independent Internal Reference Material (IRM)
- Quality products manufactured to ISO 13485: 2016 standards
- Manufactured using whole pathogens and therefore mimic the patient sample providing the best possible sample matrix for laboratories
- New controls available include Hepatitis B (HBV) Medium Q Control, Hepatitis C (HCV) Medium Q Control and HIV Medium Q Control
- US-IVD labelled for clinical use
For further information please visit https://www.randox.com/molecular-infectious-disease-controls/blood-borne-virus-testing/, visit us at stand 1101 at this year’s AACC or email market@randox.com
Total Bile Acids: The Value of Fifth Generation Tests
Bile acids are water-soluble, amphipathic end products of cholesterol metabolism and are involved in liver, biliary and intestinal diseases. They are formed in the liver and are absorbed in the small intestine before being excreted. The fundamental role of bile acids is to aid in the digestion and absorption of fats and fat-soluble vitamins in the small intestine.1
Intrahepatic Cholestasis of Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder. It can be indicated by pruritus, jaundice, elevated total bile acids and/or serum transaminases and usually affects women during the second and third trimester of pregnancy.2,3
Intrahepatic Cholestasis of pregnancy or Obstetric Cholestasis is a condition that restricts the flow of bile through the gallbladder resulting in a build-up of bile acids in the liver.3 Due to the build-up, bile acids leak into the bloodstream where they are detected at concerning levels. It is an extremely serious complication of pregnancy that can lead to the increased risk of premature birth or even stillbirth, as such it is vital that women with the disease are monitored carefully.
In healthy pregnancies, there is very little increase in total bile acid levels although a slight increase is likely to be seen in the third trimester. Measurement of total bile acids in serum is thought to be the most suitable method of diagnosing and monitoring ICP.6
According to several reports total bile acid levels in ICP can reach as high as 100 times the upper limit of a normal pregnancy. It has been reported that a doubling in maternal serum bile acids, results in a 200% increased risk of stillbirth with total bile acids thought to trigger the onset of preterm labour. Additionally, bile acids can affect the foetal cardiovascular system as it has been found that there are often cardiac rhythm disturbances in the foetus due to the elevated bile acids in circulation.5
Although it is a rare condition, with only 0.3-0.5% of women likely to develop ICP, it can have extreme risks and so it is important to properly diagnose and monitor the condition.6 ICP increases the risk of meconium staining of the amniotic fluid and is reported to be a sign of foetal distress. This complication is found in 16-58% of all ICP cases, worryingly 100% of cases have resulted in foetal death. The frequency of this condition is found to be greater in pregnancies with higher levels of serum total bile acids.
Risk factors
There are several risk factors associated with ICP such as a family history of ICP, use of oral contraceptives, assisted reproduction techniques and multiple gestation. Genetic influence accounts for approximately 15% of ICP cases. Dietary selenium is a contributing environmental factor as serum selenium levels often decrease throughout pregnancy. Further to this, incidences of ICP rise in the winter months, most likely due to the fact selenium levels are naturally less during these months.7,8
Total Bile Acids
In addition to ICP, bile acid levels are also measured in the diagnosis of other liver disorders. The bile acids test in an extremely sensitive indicator of liver function, capable of detecting changes in hepatic function before clinical symptoms arise, thus providing valuable information that standard liver function tests cannot. As a result of its high sensitivity, bile acids can be used to assess liver function in transplant patients, allowing monitoring of the transplant success and of antirejection therapy. The bile acids test is most beneficial when used in conjunction with standard liver function tests such as ALT and AST which are markers of liver damage rather than liver function.
Measurement of Total Bile Acids
The enzyme cycling method, also known as the Fifth Generation Bile Acids test, is a method that allows for signal amplification through cycled regeneration reactions as can be seen in Figure 1. In the presence of Thio-NAD, the enzyme 3-α hydroxysteroid dehydrogenase (3-α HSD) converts bile acids to 3-keto steroids and Thio-NADH. The reaction is reversible and 3-α HSD can convert 3-keto steroids and Thio-NADH to bile acids and Thio-NAD. In the presence of excess NADH, the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is determined by measuring specific change of absorbance at 405 nm and is proportional to the amount of total bile acids in the sample. The analysing capability of the fifth generation total bile acids assay is far beyond the performance of conventional bile acid tests.10,11
Figure 1: The assay principle⁹
Inadequacies of Traditional Bile Acids Assays
Determining the cause and extent of liver damage is important in guiding treatment decisions and preventing disease progression. Standard liver function tests include; ALT, AST, ALP, GGT and Bilirubin. The measurement of TBA is most beneficial in conjunction with these standard liver tests and offers unrivalled sensitivity allowing identification of early stage liver dysfunction. There are several commercial methods available for the detection and measurement of TBA in serum. Traditional TBA tests based on the enzymatic method use nitrotetrazolium blue (NBT) to form a formazan dye. The reaction is measured at 546nm and the intensity of the colour is proportional to the concentration of bile acids.
Newer methods such as the enzyme cycling method or fifth generation methods offer many advantages including greater sensitivity, liquid reagents, small sample volumes and reduced instrument contamination from formazan dye. Additionally, the fifth generation assay does not suffer from interference from lipaemic or haemolytic samples. Both lipemia and haemolysis are common in new-borns and pregnant women, so this further supports that the fifth generation test is more sensitive for these sample types.12
Want to know more?
Contact us or download our total bile acids whitepaper
Related Products
Randox Reagents
Reagents Resource Hub
High Performance & Unique Testing
References
[1] The continuing importance of bile acids in liver and intestinal disease. A.f., Hofmann. 1999, Arch Intern Med, pp. 2647-2658.
[2] Diagnostic and Therapeutic Profiles of Serum Bile Acids in Women with Intrahepatic Cholestasis of Pregnancy – A Pseudo-Targeted Metabolomics Study. Cui, Yue. Xu, Biao. Zhang, Xiaoqing. He, Yifan. Shao, Yong. Ding, Min. s.l. : Clinica Chimica, 2018, Vol. 483.
[3] Randox Laboratories. Bile Acids Test for Obstetric Cholestasis – A serious complication of pregnancy. 2012.
[4] British Liver Trust (2019) Facts about Liver Disease, Available at: https://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease/ (Accessed: 18th June 2019).
[5] .Geenes, Victoria. Williamson, Catherine. 17, s.l. : World J Gastroenterol, 2009, Vol. 15.
[6] Howland, Genevieve. Cholestasis of Pregnancy: Why You Can’t Ditch the Itch. Mama Natural. [Online] December 22, 2018. [Cited: February 19, 2019.] https://www.mamanatural.com/cholestasis-of-pregnancy/.
[7] Bile Acid Levels and Risk of Adverse Perinatal Outcomes in Intrahepatic Cholestasis of Pregnancy: A Meta-Analysis. Cui, Donghua, et al.
[8] Intrahepatic Cholestasis of Pregnancy. Chivers, Sian. Williamson, Catherine. 7, 2018, Vol. 28.
[9] Masoud, N; Neill, S.H. Serum bile acids as a sensitive biological marker for evaluating hepatic effects of organic solvents. Available from URL: https://www.ncbi.nlm.nih.gov/pubmed/23885947 [Accessed 1 November 2018]
[10] Microassay of Serum Bile Acids by an Enzymatic Cycling Method. Komiyama, Y, et al. 10, s.l. : Chemical and Pharmaceutical Bulletin, 1982, Vol. 30.
[11] Evaluation of a Colorimetric Enzymatic Procedure for Determining the Total Bile Acids in the Blood. Agape, V, et al. 3, s.l. : Minerva Gastroenterologica e Dietologica, 1989, Vol. 35.
[12] Total Bile Acids Test & Clinical Diagnosis. Diazyme. 2019.
Accreditation Release – Randox RX series gains NGSP Certification for Direct HbA1c
16th July 2019
Accreditation Release – NGSP Certified
Randox RX series gains NGSP Certification for Direct HbA1c
Randox Laboratories has today announced its achievement in being awarded the Manufacturer Certification by the National Glycohemoglobin Standardization Program (NGSP); for direct HbA1c testing on three of its clinical chemistry analysers; the RX modena, RX imola and RX daytona+.
NGSP is recommended for laboratories conducting diabetes-related clinical trials and is only granted on the basis of 98% accuracy. With the global prevalence of diabetes mellitus increasing rapidly, affecting roughly 8% of the total population, the achievement of this certification emphasises that Randox RX series clinical chemistry analysers correlate with global standards and deliver accurate, reliable and precise results for direct HbA1c testing; helping clinicians make informed decisions for patients with diabetes.
The Randox automated immunoturbidmetric HbA1c test exhibits high accuracy and reproducibility with the added advantages of using liquid reagents with good stability, and on-board pre- treatment of samples; therefore offering an improved method for the rapid direct measurement of HbA1c in human blood.
Randox Direct HbA1c Assay Features
> Sample type – suitable for use with whole blood samples
> Latex enhanced immunoassay method – the Randox assay utilises an immunoassay method making it simple and quick to perform
> Liquid ready to use reagents – for ease of use and convenience
> Excellent stability – all reagents are stable to expiry date when stored at +2-8ºC or 28 days on board the analyser at approximately 10°C
Advantages of the RX series Direct HbA1c Testing
> Fully automated on-board haemolysis function for HbA1c testing
> Continuous loading and STAT sample functionality to enhance productivity in the laboratory (analyser dependent)
> Low sample volumes required
> 1200 tests per hour including ISE (RX modena)
About Randox Laboratories
As a world leader in the in-vitro diagnostic industry with over 35 years’ experience, Randox is leading the charge in moving from a one-size-fits-all approach towards decisions, practices and products tailored to the needs of the individual. This innovative approach to diagnostics has facilitated the development of revolutionary products designed specifically to enhance a patients’ quality of life.
Want to know more?
Contact us or visit our RX page to learn more.
Related Products
RX daytona+
RX imola
RX modena
RX Overview
References
Workplace Alcohol and Drug Testing Solutions from RTS
At Randox Testing Services our workplace drug & alcohol testing programs are designed with the customer in mind. We tailor our packages to ensure that every company has the testing program in place that suits the needs of their business. We find that no two companies have the same requirements. What works for one may not necessarily work for another, so our experience in helping companies craft tailored packages has afforded us knowledge that has allowed us to build long-term customer relationships.
Have a read below about how we help companies across various markets in their efforts to provide safer workplaces by reducing the impact of drugs & alcohol.
Workplace Drug & Alcohol Testing
With the widespread availability of drugs and alcohol, there is an increased risk of substance abuse in the workplace leading to huge ramifications for a business and its employees. Jeopardising the safety of not only the user, but also their co-workers and in some cases the public, it affects the whole business environment and puts those present at serious risk of harm.
It is estimated that 1 in 20 people aged between 15-64 used an illicit drug in the past year. What’s more concerning is that 10% of these people are considered to be problem drug users. In the UK, it is estimated that £7.3 billion is lost each year due to the amount of lost work and productivity through alcohol abuse alone.
To counteract the negative effects substance misuse can have on a company, many organisations implement a policy that outlines their expectations concerning working whilst under the influence of alcohol and drugs. Employers hold the responsibility to ensure employees are fully aware of the company’s rules, regulations, testing and disciplinary procedures.
Our complete testing solutions ensure companies are provided with the necessary support and information in their efforts to implement workplace testing. Our drug & alcohol testing experts can provide information on sample types, types of testing, policy and drugs we test for; all of which are designed to ensure needs and requirements are met.
Medico-Legal Drug & Alcohol Testing
Medico-legal testing for drugs and alcohol may be required by various professional bodies involved in child custody cases, care proceedings or child protection cases. Drug & alcohol testing is important to ensure child protection from the detrimental effects of parental substance misuse and to ensure they have a quality of life they deserve.
At Randox Testing Services we provide drug & alcohol testing to all professionals within the family law and medico-legal sector. Our hair drug testing service utilised accredited testing methods and is made more cost-effective through the patented testing methods we have developed.
Our drug and alcohol testing solutions are flexible and can be tailored to our customer needs with a choice of testing methods. We offer a comprehensive drugs of abuse test menu and our service also includes expert witness reporting where applicable.
Randox Testing Services
Want to know more about the drug & alcohol testing services we offer for workplaces and professionals in the medico-legal sector? One of our experienced business development executives will be happy to discuss your requirements. Contact us using any of the below methods.
Web: www.randoxtestingservices.com
Email: testingservices@randox.com
Tel: +44 (0) 28 9445 1011
